Detalles de la búsqueda
1.
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Lancet Oncol
; 25(4): 518-528, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38547895
2.
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Gastric Cancer
; 27(2): 375-386, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38281295
3.
FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
BMC Cancer
; 21(1): 564, 2021 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34001059
4.
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Int J Cancer
; 147(11): 3177-3188, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32525595
5.
Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience.
Dis Colon Rectum
; 60(8): 785-791, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28682963
6.
Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.
Oncology
; 90(5): 261-6, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27097162
7.
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
J Clin Oncol
; 42(9): 1055-1066, 2024 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38232341
8.
Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.
Dig Liver Dis
; 2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38762353
9.
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
JAMA Oncol
; 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38573643
10.
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Eur J Cancer
; 200: 113587, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38340384
11.
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
BMJ
; 385: e078876, 2024 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38806195
12.
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Lancet Gastroenterol Hepatol
; 2024 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38823398
13.
Prognostic impact of post-treatment FDG PET/CT in anal canal cancer: A prospective study.
Radiother Oncol
; 188: 109905, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37678620
14.
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
JAMA Oncol
; 9(10): 1356-1363, 2023 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37535388
15.
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.
J Gastrointest Oncol
; 14(2): 997-1007, 2023 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37201091
16.
Failure of Initial Curative Treatment for Non-Metastatic Anal Squamous Cell Carcinoma: From Prognostic Factors Analysis to Stratified Treatment.
Clin Colorectal Cancer
; 21(4): 362-370, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35934635
17.
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
Eur J Cancer
; 168: 34-40, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35436675
18.
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
Dig Liver Dis
; 54(10): 1335-1341, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35907691
19.
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
JAMA Oncol
; 8(11): 1571-1578, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36048453
20.
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.
Front Oncol
; 12: 918499, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36119522